Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer (Review)
- Authors:
- Yinghong Huang
- Susan P.C. Cole
- Tiange Cai
- Yu Cai
-
Affiliations: Department of Traditional Chinese Medicine, College of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, P.R. China, Department of Pathology and Molecular Medicine, Division of Cancer Biology and Genetics, Queen's University Cancer Research Institute, Kingston, ON K7L 3N6, Canada, Department of Biological Sciences, College of Life Sciences, Liaoning University, Shenyang, Liaoning 110036, P.R. China - Published online on: May 17, 2016 https://doi.org/10.3892/ol.2016.4596
- Pages: 11-15
This article is mentioned in:
Abstract
 |
|
Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gottesman MM and Ling V: The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Lett. 580:998–1009. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5:302005. View Article : Google Scholar : PubMed/NCBI | |
|
Noguchi K, Katayama K, Mitsuhashi J and Sugimoto Y: Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 61:26–33. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sugimoto Y, Tsukahara S, Ishikawa E and Mitsuhashi J: Breast cancer resistance protein: Molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci. 96:457–465. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wang F, Wang YC, Dou S, Xiong MH, Sun TM and Wang J: Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano. 5:3679–3692. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Diao YY, Han M, Chen DW and Gao JQ: Progress in the study of micelle delivery system reversing multidrug resistance. Yao Xue Xue Bao. 44:710–715. 2009.(In Chinese). PubMed/NCBI | |
|
Kapse-Mistry S, Govender T, Srivastava R and Yergeri M: Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 5:1592014.PubMed/NCBI | |
|
Hu CM and Zhang L: Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab. 10:836–841. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chidambaram M, Manavalan R and Kathiresan K: Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci. 14:67–77. 2011.PubMed/NCBI | |
|
Cho K, Wang X, Nie S, Chen ZG and Shin DM: Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 14:1310–1316. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Sui M and Fan W: Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab. 11:129–141. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Markman JL, Rekechenetskiy A, Holler E and Ljubimova JY: Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 65:1866–1879. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kirtane AR, Kalscheuer SM and Panyam J: Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev. 65:1731–1747. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lao J, Madani J, Puértolas T, Alvarez M, Hernández A, Pazo-Cid R, Artal A and Antón Torres A: Liposomal doxorubicin in the treatment of breast cancer patients: A review. J Drug Deliv. 2013:4564092013. View Article : Google Scholar : PubMed/NCBI | |
|
Rivera E: Liposomal anthracyclines in metastatic breast cancer: Clinical update. Oncologist. 8(Suppl 2): 3–9. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lorusso V, Manzione L and Silvestris N: Role of liposomal anthracyclines in breast cancer. Ann Oncol. 18(Suppl 6): vi70–vi73. 2007.PubMed/NCBI | |
|
Arias JL, Clares B, Morales ME, Gallardo V and Ruiz MA: Lipid-based drug delivery systems for cancer treatment. Curr Drug Targets. 12:1151–1165. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Samad A, Sultana Y and Aqil M: Liposomal drug delivery systems: An update review. Curr Drug Deliv. 4:297–305. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lian T and Ho RJ: Trends and developments in liposome drug delivery systems. J Pharm Sci. 90:667–680. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Goyal P, Goyal K, Kumar Vijaya SG, Singh A, Katare OP and Mishra DN: Liposomal drug delivery systems-clinical applications. Acta Pharm. 55:1–25. 2005.PubMed/NCBI | |
|
Zhou WJ, Zhou W, Jia SW, et al: The cytology evaluation of doxorubicin liposomes to overcome multidrug resistance in vitro. Zhong Guo Yi Yuan Yao Xue Za Zhi. 32:1349–1352. 2012.(In Chinese). | |
|
Kang DI, Kang HK, Gwak HS, Han HK and Lim SJ: Liposome composition is important for retention of liposomal rhodamine in p-glycoprotein-overexpressing cancer cells. Drug Deliv. 16:261–267. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shidhaye SS, Vaidya R, Sutar S, Patwardhan A and Kadam VJ: Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr Drug Deliv. 5:324–331. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Li XW, Sun LX, Lin XH and Zeng LQ: Solid lipid nanoparticles as drug delivery system. Prog Chem. 19:87–92. 2007. | |
|
Xu DH, Gao JQ, Liang WQ, Yang JM and Yao Q: Progress of solid lipid nanoparticles in overcoming multidrug resistance. Zhong Guo Yao Xue Za Zhi. 45:401–403. 2010. | |
|
Wong HL, Bendayan R, Rauth AM and Wu XY: Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci. 93:1993–2008. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, Erhan SZ and Wu XY: A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 23:1574–1585. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wong HL, Rauth AM, Bendayan R and Wu XY: In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm. 65:300–308. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wong HL, Bendayan R, Rauth AM and Wu XY: Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release. 116:275–284. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shuhendler AJ, Prasad P, Zhang RX, Amini MA, Sun M, Liu PP, Bristow RG, Rauth AM and Wu XY: Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Mol Pharm. 11:2659–2674. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Prasad P, Cheng J, Shuhendler A, Rauth AM and Wu XY: A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. Drug Deliv Transl Res. 2:95–105. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Miao J, Du YZ, Yuan H, Zhang XG and Hu FQ: Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf B Biointerfaces. 110:74–80. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bourseau-Guilmain E, Béjaud J, Griveau A, Lautram N, Hindré F, Weyland M, Benoit JP and Garcion E: Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker ac133. Int J Pharm. 423:93–101. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sahoo SK and Labhasetwar V: Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2:373–383. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang MZH, Chen HG and Han J: Advances in drug carrier to overcome mdr. Jie Fang Jun Yao Xue Xue Bao. 30:256–259. 2014. | |
|
Ye G, Ke AW and Li X: The mrk-16 modified immune doxorubicin liposome in reversing multidrug resistance of cancer cells. Journal of Modern Oncology. 15:754–757. 2007. | |
|
Zhang Y, Huang Y and Li S: Polymeric micelles: Nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech. 15:862–871. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Y and Mao S: Amphiphilic polymeric micelles as the nanocarrier for peroral delivery of poorly soluble anticancer drugs. Expert Opin Drug Deliv. 9:687–700. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Croy SR and Kwon GS: Polymeric micelles for drug delivery. Curr Pharm Des. 12:4669–4684. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Adams ML, Lavasanifar A and Kwon GS: Amphiphilic block copolymers for drug delivery. J Pharm Sci. 92:1343–1355. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Han SS, Li ZY, Zhu JY, Han K, Zeng ZY, Hong W, Li WX, Jia HZ, Liu Y, Zhuo RX and Zhang XZ: Dual-pH sensitive charge-reversal polypeptide micelles for tumor-triggered targeting uptake and nuclear drug delivery. Small. 11:2543–2554. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Torchilin VP: Passive and active drug targeting: Drug delivery to tumors as an example. Handb Exp Pharmacol. 197:3–53. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kedar U, Phutane P, Shidhaye S and Kadam V: Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine. 6:714–729. 2010.PubMed/NCBI | |
|
Prabhu RH, Patravale VB and Joshi MD: Polymeric nanoparticles for targeted treatment in oncology: Current insights. Int J Nanomedicine. 10:1001–1018. 2015.PubMed/NCBI | |
|
Mao SR, Tian Y and Wang LL: Advances in drug nanocarriers: Polymer micelles. Shenyang Yao Ke Da Xue Xue Bao. 27:979–986. 2010. | |
|
Zhang HJ, Zhang C and Ping QN: Research and application of polymeric micelles as a pharmaceutically acceptable carrier. Yao Xue Jin Zhan. 26:326–329. 2002. | |
|
Saiyin W, Wang D, Li L, Zhu L, Liu B, Sheng L, Li Y, Zhu B, Mao L, Li G and Zhu X: Sequential release of autophagy inhibitor and chemotherapeutic drug with polymeric delivery system for oral squamous cell carcinoma therapy. Mol Pharm. 11:1662–1675. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yu J, Deng H, Xie F, Chen W, Zhu B and Xu Q: The potential of pH-responsive PEG-hyperbranched polyacylhydrazone micelles for cancer therapy. Biomaterials. 35:3132–3144. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ganta S and Amiji M: Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 6:928–939. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Katsman A, Umezawa K and Bonavida B: Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des. 15:792–808. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yadav S, Van Vlerken LE, Little SR and Amiji MM: Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol. 63:711–722. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Iyer AK, Singh A, Ganta S and Amiji MM: Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 65:1784–1802. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Wang Y, Zhu Y and Oupický D: Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J Control Release. 172:589–600. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hu ZX and Fu XD: The progress of nanoparticles drug delivery system in mdr of tumor and its reversal. Zhong Guo Yi Yuan Yao Xue Za Zhi. 31:1724–1727. 2011. | |
|
Chen JN, Shen Q and Li SS: Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance. Yao Xue Xue Bao. 44:333–337. 2009.(In Chinese). PubMed/NCBI | |
|
Qin Y, Li M, Qiu Q, Pi JT and Chen HY: The application of nanoparticles drug delivery system in multi-drug resistance of tumor. Xian Dai Sheng Wu Yi Xue Jin Zhan. 14:55645599. –5600. 2014. | |
|
Abouzeid AH, Patel NR and Torchilin VP: Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin e micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int J Pharm. 464:178–184. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tang J, Zhang L, Gao H, Liu Y, Zhang Q, Ran R, Zhang Z and He Q: Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity. Drug Deliv. 1–14. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Teng ZG, Huang XY and Lu GM: Mesoporous silica nanoparticles for cancer theranostic drug delivery. Yao Xue Xue Bao. 48:8–13. 2013.(In Chinese). PubMed/NCBI | |
|
Jiang XX, Yang H and Yang Y: Silicon nanometer carrier with rna interference plasmid in reversing mdr in human colon cancer. Practical Preventive Medicine. 20:1385–1389. 2013. | |
|
Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI and Tamanoi F: Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small. 6:1185–1190. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Slowing II, Vivero-Escoto JL, Wu CW and Lin VS: Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 60:1278–1288. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Vivero-Escoto JL, Slowing II, Trewyn BG and Lin VS: Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery. Expert Opin Drug Deliv. 7:1013–1029. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pan L, Liu J, He Q, Wang L and Shi J: Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials. 34:2719–2730. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
He Q and Shi J: MSN anti-cancer nanomedicines: Chemotherapy enhancement, overcoming of drug resistance and metastasis inhibition. Adv Mater. 26:391–411. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vivero-Escoto JL, Slowing II, Trewyn BG and Lin VS: Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small. 6:1952–1967. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tang F, Li L and Chen D: Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv Mater. 24:1504–1534. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Chen Y, Ji X, He X, Yin Q, Zhang Z, Shi J and Li Y: Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. ACS Nano. 5:9788–9798. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI and Nel AE: Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano. 4:4539–4550. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Li F, Guo S, Chen X, Wang X, Li J and Gan Y: Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells. Biomaterials. 35:3650–3665. 2014. View Article : Google Scholar : PubMed/NCBI |
